SVB’s lengthy shadow, pushy AI algorithms, & Icahn v. Illumina

Is AI dictating affected person care? What occurs when your financial institution falls aside? And will Illumina bear some shareholder activism?

We duvet all that and extra this week at the 250th episode of “The Readout LOUD,” STAT’s biotech podcast. STAT reporter Bob Herman joins us to give an explanation for how remedy algorithms powered via synthetic intelligence are getting used extra continuously via Medicare Benefit plans to disclaim claims, even if endured remedy is medically justified. We’ll additionally talk about the most recent information within the lifestyles sciences, together with the continuing fallout of the run on Silicon Valley Financial institution, the go back of Carl Icahn, and a long-awaited pharmaceutical megadeal.

For extra on what we duvet, right here’s the tale on AI and Medicare Benefit; right here’s the most recent on SVB; right here’s the inside track on Illumina; right here’s extra on Pfizer purchasing Seagen; right here’s the place you’ll in finding episodes of Colour Code; and right here’s the place you’ll subscribe to the First Opinion Podcast.

Remember to join on Apple Podcasts, Spotify, Stitcher, Google Play, or anyplace you get your podcasts.

And if in case you have any comments for us — subjects to hide, visitors to ask, vocal tics to stop — you’ll e-mail [email protected].